Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature

References

• Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013;27(3):391–404. doi:10.1016/j.berh.2013.07.008
   PubMed Web of Science ®Google Scholar
• Petty AJ, Floyd L, Henderson C, et al. Cutaneous lupus erythematosus: progress and challenges. Curr Allergy Asthma Rep. 2020;20(5):12. doi:10.1007/s11882-020-00906-8
   PubMed Web of Science ®Google Scholar
• Kuhn A, Sonntag M, Richter-Hintz D, et al. Phototesting in lupus erythematosus: a 15-year experience. J Am Acad Dermatol. 2001;45(1):86–95. doi:10.1067/mjd.2001.114589
   PubMed Web of Science ®Google Scholar
• Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2009;(4):CD002954. doi:10.1002/14651858.CD002954.pub2
   PubMed Web of Science ®Google Scholar
• Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part II. J Am Acad Dermatol. 2011;65(6):e195–213. doi:10.1016/j.jaad.2010.06.017
   PubMedGoogle Scholar
• Chang AY, Piette EW, Foering KP, Tenhave TR, Okawa J, Werth VP. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol. 2011;147(11):1261–1267. doi:10.1001/archdermatol.2011.191
   PubMedGoogle Scholar
• Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015;51(5):638–656. doi:10.1002/mus.24566
   PubMed Web of Science ®Google Scholar
• Quain RD, Werth VP. Management of cutaneous dermatomyositis: current therapeutic options. Am J Clin Dermatol. 2006;7(6):341–351. doi:10.2165/00128071-200607060-00002
   PubMed Web of Science ®Google Scholar
• Cobos GA, Femia A, Vleugels RA. Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol. 2020;21(3):339–353. doi:10.1007/s40257-020-00502-6
   PubMed Web of Science ®Google Scholar
• Presto JK, Okon LG, Feng R, et al. Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus. Br J Dermatol. 2018;178(6):1308–1314. doi:10.1111/bjd.16337
   PubMed Web of Science ®Google Scholar
• You H, Zhang G, Wang Q, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis. 2019;78(10):1441–1443. doi:10.1136/annrheumdis-2019-215455
   PubMed Web of Science ®Google Scholar
• Chen YL, Liu L-X, Huang Q, et al. Case report: reversal of long-standing refractory diffuse non-scarring alopecia due to systemic lupus erythematosus following treatment with tofacitinib. Front Immunol. 2021;12:654376. doi:10.3389/fimmu.2021.654376
   PubMed Web of Science ®Google Scholar
• Wenzel J, van Holt N, Maier J, et al. JAK1/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus. J Invest Dermatol. 2016;136(6):1281–1283. doi:10.1016/j.jid.2016.02.015
   PubMed Web of Science ®Google Scholar
• Kreuter A, Licciardi‐Fernandez MJ, Burmann S-N, et al. Baricitinib for recalcitrant subacute cutaneous lupus erythematosus with concomitant frontal fibrosing alopecia. Clin Exp Dermatol. 2022;47(4):787–788. doi:10.1111/ced.15044
   PubMed Web of Science ®Google Scholar
• Zimmermann N, Wolf C, Schwenke R, et al. Assessment of clinical response to janus kinase inhibition in patients with familial chilblain lupus and TREX1 mutation. JAMA Dermatol. 2019;155(3):342–346. doi:10.1001/jamadermatol.2018.5077
   PubMed Web of Science ®Google Scholar
• Joos L, Vetterli F, Jaeger T, et al. Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib. Clin Exp Dermatol. 2022;47(4):748–750. doi:10.1111/ced.15005
   PubMed Web of Science ®Google Scholar
• Fornaro M, Coladonato L, Venerito V, et al. Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus. Rheumatology. 2019. doi:10.1093/rheumatology/kez442
   PubMed Web of Science ®Google Scholar
• Maeshima K, Shibata H. Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus. Ann Rheum Dis. 2020;79(5):674–675. doi:10.1136/annrheumdis-2019-216571
   PubMed Web of Science ®Google Scholar
• De Souza A, Strober BE, Merola JF, Oliver S, Franks AG. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm. pilot study J Drugs Dermatol. 2012;11(10):1224–1226.
   PubMed Web of Science ®Google Scholar
• Mazgaj M, Picard‐Dahan C, Deschamps L, et al. Successful ustekinumab treatment in a patient with psoriasis and subacute cutaneous lupus erythematosus. Int J Dermatol. 2020;59(4):e118–e120. doi:10.1111/ijd.14773
   PubMed Web of Science ®Google Scholar
• Dahl C, Johansen C, Kragballe K, et al. Ustekinumab in the treatment of refractory chronic cutaneous lupus erythematosus: a case report. Acta Derm Venereol. 2013;93(3):368–369. doi:10.2340/00015555-1467
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. 2018;392(10155):1330–1339. doi:10.1016/S0140-6736(18)32167-6
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Maintenance of efficacy and safety of ustekinumab through one year in a phase II multicenter, prospective, randomized, double-blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus. Arthritis Rheumatol. 2020;72(5):761–768. doi:10.1002/art.41179
   PubMed Web of Science ®Google Scholar
• Ismail FF, Sinclair RD, Pinczewski J. Refractory lupus erythematosus tumidus responsive to tildrakizumab. Dermatol Ther. 2019;32(5):e13070. doi:10.1111/dth.13070
   PubMed Web of Science ®Google Scholar
• Merrill JT, Furie R, Werth VP, et al. Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000284. doi:10.1136/lupus-2018-000284
   PubMed Web of Science ®Google Scholar
• Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211–221. doi:10.1056/NEJMoa1912196
   PubMed Web of Science ®Google Scholar
• Furie R, Werth VP, Merola JF, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest. 2019;129(3):1359–1371. doi:10.1172/JCI124466
   PubMed Web of Science ®Google Scholar
• Werth VP, Fiorentino D, Sullivan BA, et al. Brief report: pharmacodynamics, safety, and clinical efficacy of AMG 811, a human anti-interferon-gamma antibody, in patients with discoid lupus erythematosus. Arthritis Rheumatol. 2017;69(5):1028–1034. doi:10.1002/art.40052
   PubMed Web of Science ®Google Scholar
• Kurtzman DJ, Wright NA, Lin J, et al. Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatol. 2016;152(8):944–945. doi:10.1001/jamadermatol.2016.0866
   PubMed Web of Science ®Google Scholar
• Moghadam-Kia S, Charlton D, Aggarwal R, et al. Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. Rheumatology. 2019;58(6):1011–1015. doi:10.1093/rheumatology/key366
   PubMed Web of Science ®Google Scholar
• Min MS, Alsarheed A, Kassamali B, et al. Tofacitinib as treatment for refractory dermatomyositis: a retrospective study from 2 academic medical centers. J Am Acad Dermatol. 2022;86(2):423–425. doi:10.1016/j.jaad.2021.07.003
   PubMed Web of Science ®Google Scholar
• Shneyderman M, Ahlawat S, Christopher-Stine L, et al. Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series. Rheumatology. 2021;60(11):e387–e388. doi:10.1093/rheumatology/keab421
   PubMed Web of Science ®Google Scholar
• Williams P, McKinney B. Refractory dermatomyositis-systemic lupus erythematosus overlap syndrome and response to tofacitinib. Proc (Bayl Univ Med Cent). 2020;34(1):116–117. doi:10.1080/08998280.2020.1821589
   PubMedGoogle Scholar
• Paik JJ, Casciola‐Rosen L, Shin JY, et al. Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients. Arthritis Rheumatol. 2021;73(5):858–865. doi:10.1002/art.41602
   PubMed Web of Science ®Google Scholar
• Yu Z, Wang L, Quan M, et al. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review. Rheumatology. 2021;60(4):1700–1707. doi:10.1093/rheumatology/keaa558
   PubMed Web of Science ®Google Scholar
• Crespo Cruz A, Del Boz J, Romero Gomez C. Good response to tofacitinib in refractory amyopathic dermatomyositis. Actas Dermosifiliogr. 2021;112(4):374–376. doi:10.1016/j.ad.2019.07.016
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Kasuya T, Fujiwara M, et al. Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: a case report. Medicine. 2020;99(37):e21943. doi:10.1097/MD.0000000000021943
   PubMed Web of Science ®Google Scholar
• Sozeri B, Demir F. A striking treatment option for recalcitrant calcinosis in juvenile dermatomyositis: tofacitinib citrate. Rheumatology. 2020;59(12):e140–e141. doi:10.1093/rheumatology/keaa360
   PubMed Web of Science ®Google Scholar
• Sabbagh S, Almeida de Jesus A, Hwang S, et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain. 2019;142(11):e59. doi:10.1093/brain/awz293
   PubMed Web of Science ®Google Scholar
• Ohmura SI, Yamabe T, Naniwa T. Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies. Mod Rheumatol Case Rep. 2021;5(1):76–81. doi:10.1080/24725625.2020.1816674
   PubMedGoogle Scholar
• Paik JJ, Christopher-Stine L. A case of refractory dermatomyositis responsive to tofacitinib. Semin Arthritis Rheum. 2017;46(4):e19. doi:10.1016/j.semarthrit.2016.08.009
   PubMedGoogle Scholar
• Hornung T, Janzen V, Heidgen F-J, et al. Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med. 2014;371(26):2537–2538. doi:10.1056/NEJMc1412997
   PubMed Web of Science ®Google Scholar
• Le Voyer T, Gitiaux C, Authier F-J, et al. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology. 2021;60(12):5801–5808. doi:10.1093/rheumatology/keab116
   PubMed Web of Science ®Google Scholar
• Heinen A, Schnabel A, Brück N, et al. Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis? Rheumatology. 2021;60(4):e136–e138. doi:10.1093/rheumatology/keaa657
   PubMed Web of Science ®Google Scholar
• Aeschlimann FA, Frémond M-L, Duffy D, et al. A child with severe juvenile dermatomyositis treated with ruxolitinib. Brain. 2018;141(11):e80. doi:10.1093/brain/awy255
   PubMed Web of Science ®Google Scholar
• Ladislau L, Suárez-Calvet X, Toquet S, et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain. 2018;141(6):1609–1621. doi:10.1093/brain/awy105
   PubMed Web of Science ®Google Scholar
• Kim H, Dill S, O’Brien M, et al. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Ann Rheum Dis. 2021;80(3):406–408. doi:10.1136/annrheumdis-2020-218690
   PubMed Web of Science ®Google Scholar
• Delvino P, Bartoletti A, Monti S, et al. Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis. Rheumatology. 2020;59(12):e125–e127. doi:10.1093/rheumatology/keaa184
   PubMed Web of Science ®Google Scholar
• Papadopoulou C, Hong Y, Omoyinmi E, et al. Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain. 2019;142(3):e8. doi:10.1093/brain/awz005
   PubMed Web of Science ®Google Scholar
• Fischer K, Aringer M, Steininger J, et al. Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib. Br J Dermatol. 2022;187:432–435. doi:10.1111/bjd.21252
   PubMed Web of Science ®Google Scholar
• Konishi R, Tanaka R, Inoue S, et al. Evaluation of apremilast, an oral phosphodiesterase 4 inhibitor, for refractory cutaneous dermatomyositis: a phase 1b clinical trial. J Dermatol. 2022;49(1):118–123. doi:10.1111/1346-8138.16179
   PubMed Web of Science ®Google Scholar
• Bitar C, Maghfour J, Ho-Pham H, et al. Apremilast as a potential treatment for moderate to severe dermatomyositis: a retrospective study of 3 patients. JAAD Case Rep. 2019;5(2):191–194. doi:10.1016/j.jdcr.2018.11.019
   PubMedGoogle Scholar
• Charlton D, Moghadam-Kia S, Smith K, et al. Refractory cutaneous dermatomyositis with severe scalp pruritus responsive to apremilast. J Clin Rheumatol. 2021;27(8S):S561–S562. doi:10.1097/RHU.0000000000000999
   PubMed Web of Science ®Google Scholar
• Campanilho-Marques R, Deakin CT, Simou S, et al. Retrospective analysis of infliximab and Adalimumab treatment in a large cohort of juvenile dermatomyositis patients. Arthritis Res Ther. 2020;22(1):79. doi:10.1186/s13075-020-02164-5
   PubMed Web of Science ®Google Scholar
• Yamada-Kanazawa S, Kajihara I, Kobayashi A, et al. Infliximab improved the refractory cutaneous involvement in a patient with dermatomyositis. Dermatol Ther. 2019;32(3):e12859. doi:10.1111/dth.12859
   PubMed Web of Science ®Google Scholar
• Huang BB, Han L-C, Liu G-F, et al. Infliximab is effective in the treatment of ulcerative colitis with dermatomyositis: a case report. World J Gastroenterol. 2020;26(46):7425–7435. doi:10.3748/wjg.v26.i46.7425
   PubMed Web of Science ®Google Scholar
• Chen D, Wang X-B, Zhou Y, et al. Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review. Rheumatol Int. 2013;33(10):2455–2458. doi:10.1007/s00296-012-2653-4
   PubMed Web of Science ®Google Scholar
• Riley P, McCann LJ, Maillard SM, et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology. 2008;47(6):877–880. doi:10.1093/rheumatology/ken074
   PubMed Web of Science ®Google Scholar
• Dold S, Justiniano ME, Marquez J, et al. Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol. 2007;26(7):1186–1188. doi:10.1007/s10067-006-0325-z
   PubMed Web of Science ®Google Scholar
• Hassan N, Davies EJ, Faber BG, et al. Infliximab in a patient with treatment-resistant anti-SAE dermatomyositis. Rheumatology. 2021;60(5):e156–e158. doi:10.1093/rheumatology/keaa698
   PubMed Web of Science ®Google Scholar
• Roddy E, Courtney PA, Morris A. Non-Hodgkin’s lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology. 2002;41(10):1194–1195. doi:10.1093/rheumatology/41.10.1194
   PubMed Web of Science ®Google Scholar
• Park JK, Yoo H-G, Ahn D-S, et al. Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with Adalimumab. Rheumatol Int. 2012;32(11):3587–3590. doi:10.1007/s00296-011-2220-4
   PubMed Web of Science ®Google Scholar
• Xie F, Williams P, Batchelor R, et al. Successful treatment of dermatomyositis and associated calcinosis with Adalimumab. Clin Exp Dermatol. 2020;45(7):945–949. doi:10.1111/ced.14325
   PubMed Web of Science ®Google Scholar
• Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011;70(3):427–436. doi:10.1002/ana.22477
   PubMed Web of Science ®Google Scholar
• Rouster-Stevens KA, Ferguson L, Morgan G, et al. Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res. 2014;66(5):783–787. doi:10.1002/acr.22198
   PubMed Web of Science ®Google Scholar
• Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol. 2006;54(3 Suppl 2):S139–42. doi:10.1016/j.jaad.2005.11.1090
   PubMed Web of Science ®Google Scholar
• Montoya CL, Gonzalez ML, Ospina FE, et al. A rare case of amyopathic juvenile dermatomyositis associated with psoriasis successfully treated with ustekinumab. J Clin Rheumatol. 2017;23(2):129–130. doi:10.1097/RHU.0000000000000430
   PubMed Web of Science ®Google Scholar
• Kim HJ, Zeidi M, Bonciani D, et al. Itch in dermatomyositis: the role of increased skin interleukin-31. Br J Dermatol. 2018;179(3):669–678. doi:10.1111/bjd.16498
   PubMed Web of Science ®Google Scholar
• Werth VP, Hejazi E, Pena SM, et al. Safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: a randomized clinical trial. J Invest Dermatol. 2022. doi:10.1016/j.jid.2022.03.029
   Web of Science ®Google Scholar
• Shi H, Gudjonsson JE, Kahlenberg JM. Treatment of cutaneous lupus erythematosus: current approaches and future strategies. Curr Opin Rheumatol. 2020;32(3):208–214. doi:10.1097/BOR.0000000000000704
   PubMed Web of Science ®Google Scholar
• Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol. 2019;15(9):519–532. doi:10.1038/s41584-019-0272-0
   PubMed Web of Science ®Google Scholar
• Kao L, Chung L, Fiorentino DF. Pathogenesis of dermatomyositis: role of cytokines and interferon. Curr Rheumatol Rep. 2011;13(3):225–232. doi:10.1007/s11926-011-0166-x
   PubMed Web of Science ®Google Scholar
• Salomonsson S, Lundberg IE. Cytokines in idiopathic inflammatory myopathies. Autoimmunity. 2006;39(3):177–190.
   PubMed Web of Science ®Google Scholar
• Niewold TB, Kariuki SN, Morgan GA, et al. Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis. J Pediatr. 2010;157(4):653–657. doi:10.1016/j.jpeds.2010.04.034
   PubMed Web of Science ®Google Scholar